Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the ...

The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with ...

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

Takeda is rolling out its first rare disease CTV campaign for its chronic inflammatory demyelinating polyneuropathy (CIDP) ...

The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-sev ...

This stability supports the administration of luspatercept once every 3 weeks. In this study, luspatercept was administered ...

Sarcopenia and Muscle Loss After age 30, muscle loss begins, and by 40, the effects accelerate. This process, known as ...

A study found that people who engaged in consistent physical activity had a greater ability to store fat subcutaneously ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

The FDA has granted Breakthrough Therapy designation to the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta in adults.